● First-line drugs for antiviral treatment of chronic hepatitis B ● China Guidelines for Prevention and Treatment of Chronic Hepatitis B, European Society of Hepatology (EASL), American Society of Hepatology (AASLD) and Asia-Pacific Society of Hepatology (APASL)*** are all recommended as first-line drugs for chronic hepatitis B.
● A new generation of nucleotide analogues
● It is suitable for patients who are newly treated and re-treated, with quick and obvious effect ● It is active against wild strains, lamivudine and entecavir resistant mutants of hepatitis B virus.
Long-term inhibition of hepatitis B virus, not easy to appear drug resistance.
Three major patent technical guarantees
It has three patent protection technologies: M crystal form, preparation and detection of adefovir dipivoxil monoester, and synthesis process. The patent system is complete, the synthesis process is advanced, the route is mature, and the quality is stable.
Adefovir is a crystal with diester, which is easy to shed an ester and become an impurity monoester, so the storage environment is particularly important. Agandine has a unique nested design, double-layer bottle body, low oxygen permeability and water permeability, better heat insulation, and ensures stable drug quality. It has a patent for packaging design, patent number ZL 200730139046.2; ;
Less impurities and higher standards.
There are the strictest control standards for related substances (impurities).
(See Drug Quality Standards of State Administration of Pharmaceutical Products)
The content of related substances (impurities) in the finished product is only 1%, which is higher in purity, better in quality and safer.
The unique M crystal form is easy to absorb.
The unique M crystal form is easier to be absorbed and has higher bioavailability.
M crystal form. The melting point is lower than that of crystal form I, the solubility is higher, it is more easily absorbed by human body, and the bioavailability is higher.
In 2009, Guangshengtang Adefovir Dipivoxil Industrialization Project was listed as "Independent Innovation High-tech Industrialization Support Project" by the National Development and Reform Commission.
In 2009, Guangshengtang Agandine-Adefovir Dipivoxil Tablets won the first prize of excellent new products in Fujian Province.
On 20 10, Guangshengtang Agandine-Adefovir Dipivoxil Tablets won the first prize of scientific and technological invention and the special prize of patent in Fujian Province.